Daytrana and Application site erosion - a phase IV clinical study of FDA data

Summary:

Application site erosion is reported as a side effect among people who take Daytrana (methylphenidate), especially for people who are male, 2-9 old, have been taking the drug for < 1 month also take Melatonin, and have Gun shot wound.

The phase IV clinical study analyzes which people have Application site erosion when taking Daytrana. It is created by eHealthMe based on reports of 16,266 people who have side effects when taking Daytrana from the FDA, and is updated regularly.

What is Daytrana?

Daytrana has active ingredients of methylphenidate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 16,561 Daytrana users. Check the latest studies of Daytrana.

What is Application site erosion?

Application site erosion is found to be associated with 107 drugs and 282 conditions by eHealthMe. Check the latest studies of Application site erosion.

On Aug, 11, 2026

16,266 people reported to have side effects when taking Daytrana.
Among them, 67 people (0.41%) have Application site erosion.

Could Daytrana cause Application site erosion?

Among these 67 people:

How long have people been on Daytrana when they have Application site erosion? *

What is the gender of people who have Application site erosion when taking Daytrana? *

female: 39.58 %
male: 60.42 %

What is the age of people who have Application site erosion when taking Daytrana? *

What are other drugs people take besides Daytrana? *

Melatonin: 3 people, 4.48%
Singulair: 2 people, 2.99%
Klonopin: 2 people, 2.99%
Mirtazapine: 2 people, 2.99%
Zyrtec: 2 people, 2.99%
Topiramate: 2 people, 2.99%
Tenex: 1 person, 1.49%
Hydrocodone: 1 person, 1.49%
Advair Hfa: 1 person, 1.49%
Albuterol Sulfate And Ipratropium Bromide: 1 person, 1.49%

What are other side effects people have besides Application site erosion? *

Application Site Erythema (redness of the skin at application site): 36 people, 53.73%
Application Site Irritation: 23 people, 34.33%
Application Site Pruritus (application site severe itching of the skin): 18 people, 26.87%
Application Site Swelling: 12 people, 17.91%
Application Site Pain: 11 people, 16.42%
Application Site Dryness: 9 people, 13.43%
Application Site Scab (hard coating on the skin formed at application site): 7 people, 10.45%
Application Site Rash: 6 people, 8.96%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 8.96%
Application Site Urticaria: 4 people, 5.97%

What are the existing conditions these people have? *

Seasonal Allergy (allergic condition due to certain season): 2 people, 2.99%
Insomnia (sleeplessness): 2 people, 2.99%
Gun Shot Wound: 2 people, 2.99%
Sinus Disorder (disease of sinus): 1 person, 1.49%
Quit Smoking: 1 person, 1.49%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 1 person, 1.49%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 1.49%
Joint Pain: 1 person, 1.49%
High Blood Pressure: 1 person, 1.49%
Gilles De La Tourette Syndrome (a condition that causes people to make repeated, quick movements or sounds that they cannot control): 1 person, 1.49%

* Approximation only. Some reports may have incomplete information.

Do you take Daytrana and have Application site erosion?

- Check whether Application site erosion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Daytrana:

Daytrana (16,561 reports)

Browse all side effects of Daytrana:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site erosion:

Application site erosion (107 drugs)

Browse all the conditions that are associated with Application site erosion:

Application site erosion (282 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methylphenidate (the active ingredients of Daytrana) and Daytrana (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.